RGT-018, is a potent and selective inhibitor of SOS1. It blocks the interaction of KRAS:SOS1 with an IC50 of 8 nM and inhibited KRAS signaling and the proliferation of KRAS-driven cancer cells. It may exhibit potent anticancer activity against NSCLC, colorectal cancer, and pancreatic cancer.

RGT-018, is a potent and selective inhibitor of SOS1. It blocks the interaction of KRAS:SOS1 with an IC50 of 8 nM and inhibited KRAS signaling and the proliferation of KRAS-driven cancer cells. It may exhibit potent anticancer activity against NSCLC, colorectal cancer, and pancreatic cancer.

OPB-171775 functions as a molecular glue, promoting the formation of a complex between phosphodiesterase 3A (PDE3A) and Schlafen family member 12 (SLFN12). This interaction triggers multiple cellular stresses, ultimately leading to cell death. It also demonstrates significant anticancer activity in patient-derived xenograft (PDX) models of Gastrointestinal stromal tumor (GIST).

OPB-171775 functions as a molecular glue, promoting the formation of a complex between phosphodiesterase 3A (PDE3A) and Schlafen family member 12 (SLFN12). This interaction triggers multiple cellular stresses, ultimately leading to cell death. It also demonstrates significant anticancer activity in patient-derived xenograft (PDX) models of Gastrointestinal stromal tumor (GIST).

OPB-171775 functions as a molecular glue, promoting the formation of a complex between phosphodiesterase 3A (PDE3A) and Schlafen family member 12 (SLFN12). This interaction triggers multiple cellular stresses, ultimately leading to cell death. It also demonstrates significant anticancer activity in patient-derived xenograft (PDX) models of Gastrointestinal stromal tumor (GIST).

EVT801 is a potent and selective inhibitor of VEGFR-3 with an IC50 of 11 nM. It exhibits potent antitumor effects and represents a promising anti-lymphangiogenic drug in patients with VEGFR-3 positive tumors.

EVT801 is a potent and selective inhibitor of VEGFR-3 with an IC50 of 11 nM. It exhibits potent antitumor effects and represents a promising anti-lymphangiogenic drug in patients with VEGFR-3 positive tumors.

EVT801 is a potent and selective inhibitor of VEGFR-3 with an IC50 of 11 nM. It exhibits potent antitumor effects and represents a promising anti-lymphangiogenic drug in patients with VEGFR-3 positive tumors.

EVT801 is a potent and selective inhibitor of VEGFR-3 with an IC50 of 11 nM. It exhibits potent antitumor effects and represents a promising anti-lymphangiogenic drug in patients with VEGFR-3 positive tumors.

THZ-P1-2 is an inhibitor of PI5P4K, which covalently binds to cysteines on a disordered loop in PI5P4Kα/β/γ. It inhibits PI5P4Kα kinase activity with an IC50 of 190 nM and disrupts autophagy by impairing autophagosome clearance and increasing TFEB nuclear localization.